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FOREWORD 
 
This report describes the characteristics of patients with bladder cancer and their care in 2010 and 2011. 
Survival of women with bladder cancer is lower than men, and in N. Ireland was lower in published 
international survival data. This audit allowed this to be explored further. Unfortunately late diagnosis is a 
recurring theme in the cancer arena and we must work hard with the public and professionals to reduce delay. 
I am pleased to read that overall services are provided by well functioning teams. We need to improve access 
to specialist diagnostic and support services and reduce delays in investigation and treatment.  
 
This report provides valuable information which is essential in helping us to track progress and identify those 
areas where change is needed. This report highlights the importance of the collaborative work between the 
Cancer Registry, Guidelines and Audit Implementation Network (GAIN) and clinicians in providing a leading 
role in monitoring cancer care within Northern Ireland and Commissioners and providers of service. 
 
 
 
Dr. Michael McBride 
Chief Medical Officer 
January 2014 
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INTRODUCTION 
 
Aims 
1. To detail the care pathway of bladder cancer patients in N. Ireland and assess compliance with 
recommended guidelines for investigation and treatment.  
2. To explore reasons for differences in bladder cancer survival in women compared to men. 
3. To serve as a benchmark for further audits. 
4. To make recommendations for service improvement if necessary. 
 
Background 
This report, the 10th in the current audit series undertaken by the N. Ireland Cancer Registry, describes the 
characteristics of patients with bladder cancer and their care pathway in 2010 and 2011. It was requested by 
the clinicians, who treat bladder cancer, and who were concerned about the reported poor survival in 
EUROCARE-41 of women with bladder cancer in N. Ireland when compared internationally. 
 
Changes in cancer service provision have been driven by recommendations and guidance developed by 
several working groups and public bodies over the past 15 years.  
 
Documents providing guidance for better service provision of bladder cancer patients are: 
 Cancer Services: Investing for the Future (1996)2, or more commonly known as The Campbell Report, 
was a landmark report arising from the work of clinicians, service planners and patients who worked 
together with the aim of improving cancer services in N. Ireland.  
 Cancer Services: Investing for the Future. Cancer Working Group Sub-group reports3, documents 
recommendations, arising from the Campbell Report, for bladder cancer services in N. Ireland.  
 A Cancer Control Programme for Northern Ireland4 (2008) was developed by the Department of 
Health, Social Services and Public Safety to set out clear standards for the quality of cancer care in 
Northern Ireland over the next ten years.  
 The Service Framework for Cancer Prevention Treatment and Care5 (2008) prioritised the 
recommendations coming out of the A Cancer Control Programme for Northern Ireland4. Overarching 
Standard Number 45 directly relates to bladder cancer:  “Radical surgery for prostate and bladder 
cancer should be provided by teams carrying out a total of at least 50 such operations per annum and 
should take place on a single site, which offers appropriate post-operative care”. 
 The National Institute for Clinical Excellence (NICE) produced guidelines which dealt with bladder 
cancer: Improving outcomes in urological cancers (2002)6. 
 Scottish Intercollegiate Guidelines Network (SIGN) produced Management of transitional cell 
carcinoma of the bladder- a national clinical guideline7 in 2005. 
 The British Association of Urological Surgeons (BAUS) and the British Uro-oncology Group (BUG) 
have jointly developed guidance Multi-disciplinary Team Guidance for Managing Bladder Cancer8 in 
2013.
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 The European Association of Urology issued Guidelines on Non-muscle-invasive bladder cancer 
(TaT1 and CIS)9 and Guidelines on bladder cancer muscle-invasive and metastatic10 in 2013. 
 The National Comprehensive Cancer Network (NCCN) issued guidelines Bladder Cancer11 in 2013. 
 Appendix A presents a summary of bladder cancer aetiology and treatment with recommendations, 
that largely reflects the guidance listed above. In addition, standards and waiting time targets as laid 
down by the Department of Health, Social Services and Public Safety Northern Ireland 
(DHSSPSNI)2,3,5 are included where relevant. 
 
Areas for Audit 
This report includes the following areas of audit which were considered important in delivering care according 
to the recommendations laid out in Appendix A. 
 
Areas of Audit include: 
1. Referral and presentation. 
2. Patient factors – lifestyle, family history, comorbidities, and symptoms. 
3. Investigations, in particular cystoscopy and tumour stage. 
4. Stage-specific treatments received, i.e. oncology, surgery, or palliative supportive care. 
5. Patient survival. 
6. Number of Trusts with haematuria clinic services that perform a range of diagnostic services in the 
one appointment (sometimes referred to as ‘one-stop clinic’) for patients with haematuria (blood in the 
urine). 
7. Number of hospitals in N. Ireland providing cystoscopy and transurethral resection of the bladder 
(TURB). 
8. Multidisciplinary team meetings. 
9. Timelines from referral to presentation, investigations, staging and treatment. 
10. Surgeon case volumes for major procedures, such as cystectomy/cystoprostatectomy, and the 
proportion of these carried out by specialist uro-oncology surgeons. 
11. Additional care services e.g. physiotherapy, palliative care, social worker.  
12. Patient information.  
13. Communication with primary care. 
 
Note: Data sources for the audit were clinical notes (where available), electronic patient records and pathology 
reports.
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OVERVIEW OF BLADDER CANCER IN N. IRELAND 
 
Incidence 2007-2011 
Transitional cell carcinoma (TCC) of the bladder was the 8th most common cancer in men and 16th in women 
accounting for 2.6% of all cancers (excluding non-melanoma skin cancer), with an average 154 men and 60 
women being diagnosed annually.  The higher incidence in men 2.6:1 is likely largely related to 
lifestyle/occupational risk factors (Appendix A, Risk factors). The European age-standardised rate was 
16/100,000 for men and 5/100,000 for women. The cumulative risk of getting the disease (from age 0 to 74) 
was 1.2% (1 in 86) in men and 0.3% (1 in 323) in women. Age-specific rates in both men and women increase 
with age, though the age-decade in which most patients are diagnosed is the 70s (Fig. 1). The median age at 
diagnosis is 74. There is evidence that bladder cancer rates (2002-2011) are associated with socio-economic 
deprivation in N. Ireland being higher in more deprived areas; this may be due to higher prevalence of smoking 
in deprived areas. 
 
Figure 1: Age distribution of patients diagnosed with bladder cancer in N. Ireland 
2007-2011 by sex, with age-specific rates 
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Incidence trends 1993-2011 
Although, the numbers of people diagnosed has remained relatively constant from 1993 to 2011, age-
standardised rates (Fig. 2) have been falling by 1.7% (P<0.01) per year in men, and 1.3% (P=0.13) in women. 
This fall in age-standardised rates while total numbers remains stable reflect the ageing of the population. The 
faster-falling standardised-incidence rates in men possibly reflect changes in smoking-habits between the 
sexes. 
Figure 2: Number of new cases of bladder cancer in N. Ireland from 1993 to 2011 by sex, with European 
age-standardised incidence rate 
 
 
Deaths 2007-2011 
Bladder cancer was the 7th most common cause of cancer death in men and 15th in women. It accounted for 
2.7% of all cancer deaths, with an average of 73 men and 32 women dying annually. The age-standardised 
mortality rate was 7.4/100,000 and 2.2/100,000 for men and women, respectively. The cumulative risk of dying 
from the disease (from age 0 to 74) was 0.4% (1 in 955) in men and 0.1% (1 in 247) in women. The median 
age at death was 78 years. 
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OVERVIEW OF BLADDER CANCER IN N. IRELAND 
 
Trends in mortality 1974-2011 
Age-standardised mortality rates (Fig. 3) have been falling by 0.7% (P<0.01) per year in men, and 0.5% 
(P=0.10) in women.  
 
Figure 3: Numbers of deaths from bladder cancer in N. Ireland from 1974 to 2011 by sex, plus 
European age-standardised mortality rate 
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Net survival in N. Ireland 1997-2006 
Net survival is the cancer survival in the absence of other causes of death.  It is achieved by adjusting for and 
removing the effect of population background mortality rates. It is considered a better estimate of survival than 
‘relative survival’ which gives undue weight to younger patients when estimating survival. 
 
The 5-year net survival from bladder cancer for patients diagnosed from 1997-2006 in N. Ireland was 58.7%. 
However, for patients diagnosed over 10-year period (1997-2006) and followed-up to 2011, there is a 
significantly lower survival for women than men, by a magnitude of 10% (Fig. 4a). 
 
Figure 4a: Net survival of patients diagnosed with bladder cancer from 1997 to 2006 
followed-up till 2011, by sex 
 
 
Over time since 1993 5 year net survival from bladder cancer has remained steady at approximately 60% for 
men and 40% for Women (Fig. 4b). 
 
Figure 4b: N. Ireland survival at 5 years for males and females over time 
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International comparisons 
 
Incidence: 1998-2007 
Incidence rates of bladder cancer in N. Ireland (male 11.8/100,000, female 3.2/100,000 [world age-
standardised rate]) during 1998-2002 were among the lowest in the Western World being significantly lower 
than most European countries, including the rest of the UK12. By 2003-2007 rates in N. Ireland had increased 
to 18.3/100,000 and 5.5/100,000 for males and females respectively, both of which were similar to the rates in 
England although they were still lower than those in Scotland and Denmark among others. (Fig. 5) 
 
Relative survival: 1995-2007 
The five-year (age-standardised) relative survival for bladder cancer patients diagnosed in 1995-1999 in N. 
Ireland was poor in comparison to the European average and England & Wales. The rate in men (65.0%) was 
comparable to Scotland, Slovenia, Poland, and France, but for women N. Ireland (54.6%) had the lowest 
survival rate among the EUROCARE-41 countries (Fig. 6). The EUROCARE-513 data for patients diagnosed in 
2000-2007 indicates that survival in N. Ireland was better than the European average for men and was similar 
to the average for women. However N. Ireland has a small number of female bladder cancers diagnosed each 
year, with the result that survival estimates fluctuate from year to year. 
 
Impact of coding standards 
International comparisons of bladder cancer are difficult due to the different coding classification in different 
countries with many registries assigning malignant status to non-invasive (pTa/CIS) diagnoses.  Typically 
international comparisons include non-invasive bladder cancer as malignant. The N. Ireland Cancer Registry 
does not report tumours with morphology codes, 8120/2 (flat carcinoma in situ of urothelium) 8130/1 & 8130/2, 
as bladder cancer, whereas they are included as bladder transitional cell carcinoma in Cancer Incidence in 
Five Continents12.   
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Figure 5: International comparison of world age-standardised incidence rates for men and women 
diagnosed between 1998 and 2007 (Source: Cancer Incidence in Five Continents (CIV)12) 
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Figure 6: International comparison of age-standardised relative survival rates for men and women 
diagnosed between 1998 and 2007. (Source: EUROCARE-4 & 51,13) 
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METHODOLOGY 
 
Bladder cancer was identified using the ICD1014 code ‘C67’; this selection excludes non-invasive pTa/pTis 
tumours.  
 
Audit data collection 
The data items collected in the audit were agreed following consultation with urology clinicians. An electronic 
proforma, developed in Microsoft Access, was used to collect the audit information. It was populated 
electronically with patient details extracted from the NICR database in 2012.  However, as not all items 
required for the audit were available on the NICR database, data from the Cancer Patient Pathway System 
(CaPPS) and the Clinical Oncology Information System (COIS) was extracted by the Registry Tumour 
Verification Officers (TVOs), who also examined the clinical notes when available. Inconsistencies between the 
four different datasets were then resolved, and after validation checks were complete, a detailed dataset was 
imported to the Stata statistical software for analysis. Data collection was completed in May 2013, with final 
data cleaning finished in October 2013. 
 
In order to provide geographic and socio-economic information, the 2011 central postcode directory was used 
to assign patients to a census output area (COA) based upon their postcode of usual residence. The COA was 
then used to assign a Health and Social Care Trust of residence and a deprivation quintile from the income 
domain of the 2010 multiple deprivation measure15 with the latter used to provide an approximate socio-
economic classification for each patient. 
 
Limitations 
While every effort has been made to obtain all the required information on each patient, there were several 
limitations imposed upon the collection of data: 
 Outpatient records of private patients (n=26) were sometimes unavailable resulting in some missing 
information on presentation dates and follow up. 
 The Multidisciplinary Team Meeting data download from CaPPS was not complete for all patients at 
the time of data extraction. 
 Discharge letters from the Belfast City Hospital (where most surgery was performed) were not always 
available in the patient notes held in other hospitals. In each of the above scenarios alternative 
sources of information were explored. 
 
Exclusions 
Patients were excluded from the audit if their records lacked sufficient information (n=6) or if information was 
available only from a death certificate (DCO) (n=2). 
 
Private patients 
In this study, we have defined private patients as those patients who presented via the private sector. 
Although, these patients may enter the NHS later for investigations and treatment, they are not included in the 
timeline analysis, but are included for any care in the NHS. 
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Data analysis 
The majority of results are presented in tables in which patients are classified in various categories (such as 
‘mode of presentation’ or ‘hospital of presentation’) yielding numbers and proportions. Caution must be 
exercised when comparing such proportions as apparent differences might well be explained by random 
chance; a valid statistical test is required to demonstrate significance. In addition, in large tables the probability 
is greater still of concluding a difference when none, in fact, exists; special statistical tests are required where 
this danger, arising from ‘multiple comparisons’, exists. The chi-square test is used to test for differences in the 
distribution of a categorical variable between two groups (e.g. males vs females) of another categorical 
variable. For continuous variables, a t-test is employed to compare groups. In all tests a 95% confidence level 
is applied. A non-parametric test, the log-rank test, is used to compare timeline duration distribution between 
groups of patients (e.g. men versus women). 
 
In this report, net survival has been estimated to describe the survival of patients; net survival can be 
considered as the theoretical survival of cancer patients if they could not die from other causes. It is 
appropriate for comparing the survival experience of cancer patients from different territories or calendar 
periods where background population mortality rates are different. It is used here to refine the analysis of the 
survival data of bladder cancer patients, so that differences between men and women can be explored. 
 
All patients were followed-up to ascertain if alive until the end of May 2013, giving a minimum follow-up of 1.4 
years for all patients, at least 2 years follow-up for two thirds (242/362) of all patients. Assuming that follow-up 
length is independent of dying from cancer, net survival estimates at 2 years can be estimated. Net survival 
analysis was implemented using the user-led stns16 command in Stata. 
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RESULTS 
 
Study Population 
 
Table 1: Study patients 
Total patients Year diagnosed 2010 & 2011 
Invasive bladder cancer  370 
Death certificate only cases excluded 2 
Exclusion – Insufficient information 6 
Total reported on (% of bladder cancer patients) 362 (98.4%) 
% Male 72.9% 
 
 In the 2-year audit period 2010 to 2011, 370 patients were diagnosed with invasive bladder cancer in N. 
Ireland. As only 8 patients were excluded from the audit, case ascertainment was very good (98.4%). 
 
Table 2: Age at diagnosis 
Age at diagnosis 2010 & 2011 (n=362) 
 Male (n=264) Female (n=98) Total 
Under 65 68 (25.8%) 19 (19.4%) 87 (24.0%) 
65 to 74 87 (33.0%) 22 (22.4%) 109 (30.1%) 
75 to 79 44 (16.7%) 25 (25.5%) 69 (19.1%) 
80 and over 65 (24.6%) 32 (32.7%) 97 (26.8%) 
Mean age 72.1 74.1 72.7 
Median age 73.2 76.3 74.0 
 
 The median age at diagnosis was 74 years. Invasive bladder cancer was much more common in men with 
a ratio of (2.7: 1).  A significantly higher proportion of women than men were age 75 years or over (58% vs 
41%, P<0.05). 
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RESULTS 
 
Lifestyle 
 
 Just under three quarters (72%) of all patients were current or ex-smokers with men being significantly 
more likely to be current or ex-smokers compared to women 75.8% vs 61.2% (P<0.01) (Table 3). Women 
were more likely to live alone, most likely due to the lower life-expectancy of men. 
 
Table 3: Patient lifestyle factors 
Lifestyle factors 2010 & 2011 
 Male (n=264) Female (n=98) Total (n=362) 
Lives with spouse/partner/relative  76.1% 52.0% 69.6% 
Lives alone 14.8% 37.8% 21.0% 
Lives in residential setting* 4.6% 6.1% 4.9% 
Current smoker 27.3% 30.6% 28.2% 
Ex-smoker 48.5% 30.6% 43.7% 
Never or non-smoker 20.8% 33.7% 24.3% 
Recorded history of alcohol abuse 5.3% 2.0% 4.4% 
*Hostel, nursing home, residential home, sheltered dwelling/fold 
 
Comorbidities 
 
 The majority (78%) of patients with bladder cancer had at least one comorbidity. Hypertension (48.3%), 
cardiovascular disease (31.2%), obesity (21.3%) and chronic obstructive pulmonary disease (19.6%), 
were the most common comorbidities recorded (Table 4). 
 The percentage of patients with each comorbidity did not differ significantly (P>0.10) between men and 
women (not shown). 
 
Table 4: Comorbidities 
Comorbidity  Patients (% of Total) 
Chronic obstructive pulmonary disease 71 (19.6%) 
Cardiovascular disease 113 (31.2%) 
Cerebrovascular disease 44 (12.2%) 
Diabetes 61 (16.9%) 
Hypertension 175 (48.3%) 
Dementia 20 (5.5%) 
Psychiatric disorder 30 (8.3%) 
Cancer other than bladder 28 (7.7%) 
Renal disease 58 (16.0%) 
Obesity 77 (21.3%) 
Note: patients may have more than one comorbidity  
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Charlson Comorbidity Score 
 
The Charlson comorbidity score17 is a summary statistic of both the age and level of comorbidity a patient has 
that is related to their life expectancy or risk of mortality. It is used here to describe and compare groups of 
patients (e.g. men and women). Appendix B gives more detail on how it is calculated for each patient. 
 
Table 5: Charlson comorbidity score (see Appendix B for components) 
Charlson score Number (% of total) 
 Male (n=264) Female (n=98) Total (n=362) 
1 to 4 (low) 37 (14.0%) 13 (13.3%) 50 (13.8%) 
5 to 6* 99 (37.5%) 33 (33.7%) 132 (36.5%) 
7 to 9 104 (39.4%) 41 (41.8%) 145 (40.1%) 
10 to 16 (high) 24 (9.1%) 11 (11.2%) 35 (9.7%) 
* A Charlson score of 6 predicts a 10-year-survival probability ≤2%17 
 
 Half of bladder cancer patients had a Charlson comorbidity score of 7 or greater. There was no difference 
in the distribution of Charlson scores between the men and women (P=0.86). 
 
Family History of Cancer 
 
Table 6: Family history* of cancer 
Family history 2010 & 2011 (n=362) 
 Male (n=264) Female (n=98) Total (n=362) 
Yes 58 (22.0%) 27 (27.6%) 85 (23.5%) 
No 111 (42.0%) 36 (36.7%) 147 (40.6%) 
Not recorded 95 (36.0%) 35 (35.7%) 130 (35.9%) 
* a first or second degree relative 
 
 A positive family history of cancer was recorded in 23.5% of patients. 
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Bladder Cancer Pathway: Referral and Presentation 
 
Table 7: Referral source  
Referral source 2010&2011 
 Male (n=264) Female (n=98) Total (n=362) 
GP referral to outpatients (Total) 131 (49.6%) 38 (38.8%) 169 (46.7%) 
 GP - Red flag to outpatients 55 (20.8%) 11 (11.2%) 66 (18.2%) 
 GP - Urgent/Semi-urgent 19 (7.2%) 6 (6.1%) 25 (6.9%) 
 GP - Routine 11 (4.2%) 2 (2.0%) 13 (3.6%) 
 GP - Consultant upgrade 37 (14.0%) 16 (16.3%) 53 (14.6%) 
 GP - Not known/specified 9 (3.4%) 3 (3.1%) 12 (3.3%) 
A&E Total 49 (18.6%) 26 (26.5%) 75 (20.7%) 
 Self-referral  21 (8.0%) 8 (8.2%) 29 (8.0%) 
 GP 22 (8.3%) 16 (16.3%) 38 (10.5%) 
 Non-specified 6 (2.3%) 2 (2.0%) 8 (2.2%) 
Other consultant 24 (9.1%) 17 (17.3%) 41 (11.3%) 
Under regular outpatient review 33 (12.5%) 10 (10.2%) 43 (11.9%) 
Private sector 17 (6.4%) 2 (2.0%) 19 (5.2%) 
Other 9 (3.4%) 4 (4.1%) 13 (3.6%) 
Not known 1 (0.4%) 1 (1.0%) 2 (0.6%) 
 
 In the 2 year audit period over half (57%) of all patients were referred by their GPs (to outpatients or A&E). 
 Overall 18% of patients were referred to outpatients by GPs as red flag suspect cancers and a further 
14.6% were upgraded by consultants to a red flag pathway.  GP referrals to A&E accounted for 10.5% 
while 11% were GP routine/urgent/semi-urgent/ referrals to outpatients. 
 12% of patients were under regular outpatient review at the time of diagnosis. 
 21% of patients presented via A&E. Although a higher percentage of women presented at A&E compared 
to men, this was not significant (P=0.10). 
 
Bladder Cancer Detected During Urological Surveillance 
 
 33 patients diagnosed with invasive bladder cancer in 2010/2011 were under urological surveillance 
following previous TURB where either non-invasive pTa (n=19) and/or carcinoma in situ (n=4) was found. 
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Trust and Hospital First Presentation 
 
Table 8: Trust and Hospital of first presentation (this table excludes patients that were under regular hospital 
review when bladder cancer was diagnosed [n=43]) 
Trust & hospital of first presentation 2010 & 2011  
 Total (n=319) 
Belfast City Hospital 65 (20.4%) 
Royal Victoria Hospital 6 (1.9%) 
Mater Infirmorum Hospital 13 (4.1%) 
Belfast HSCT 84 (26.3%) 
Antrim Area Hospital 8 (2.5%) 
Causeway Hospital 41 (12.9%) 
Mid-Ulster Hospital 1 (0.3%) 
Whiteabbey Hospital 1 (0.3%) 
Northern HSCT 51 (16.0%) 
Ulster Hospital 24 (7.5%) 
Lagan Valley Hospital 27 (8.5%) 
Downe Hospital 6 (1.9%) 
Ards Hospital 6 (1.9%) 
Bangor Hospital 2 (0.6%) 
South-Eastern HSCT 65 (20.4%) 
Craigavon Area Hospital 44 (13.8%) 
Daisy Hill Hospital 16 (5.0%) 
Southern HSCT 60 (18.8%) 
Altnagelvin Hospital 34 (10.7%) 
Erne Hospital 3 (0.9%) 
Tyrone County Hospital 2 (0.6%) 
Western HSCT 39 (12.2%) 
Ulster Independent Clinic 18 (5.6%) 
Hillsborough Private Clinic 1 (0.3%) 
Private Sector 19 (6.0%) 
Unknown 1 (0.3%) 
 
 Over a quarter of patients first-presented to the Belfast Trust. 
 6% of patients presented via the private sector. 
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Location of First Seen 
 
Table 9: Location of first presentation (this table excludes patients that were under regular hospital review when bladder 
cancer was diagnosed [n=43]) 
Location first seen 2010 & 2011 
 Male (n=231) Female (n=88) Total (n=319) 
Outpatients 144 (54.5%) 43 (43.9%) 187 (51.7%) 
Haematuria clinic 40 (15.2%) 16 (16.3%) 56 (15.5%) 
A&E, followed by admission 32 (12.1%) 19 (19.4%) 51 (14.1%) 
A&E, other 17 (6.4%) 7 (7.1%) 24 (6.6%) 
Private sector 17 (6.4%) 2 (2.0%) 19 (5.2%) 
Inpatients 11 (4.2%) 9 (9.2%) 20 (5.5%) 
Not known 3 (1.1%) 2 (2.0%) 5 (1.4%) 
 
 52% of patients were first seen in outpatient clinics, with a further 16% being first seen at a designated 
haematuria clinic. 
 21% of patients presented at A&E. 
 Although there were a higher proportion of women first seen at A&E, the proportion of patients first seen in 
any of the locations above did not differ significantly (P>0.05) between men and women. 
 
Speciality First Seen 
 
Table 10: Speciality first seen (patients under-review at time of diagnosis [n=43] are excluded) 
Speciality first seen 2010 & 2011 
 Male (n=231) Female (n=88) Total (n=319) 
Urology 209 (90.5%) 64 (72.7%) 273 (85.6%) 
General/Geriatric Medicine 7 (3.0%) 9 (10.2%) 16 (5.0%) 
General Surgery 7 (3.0%) 7 (8.0%) 14 (4.4%) 
Gynaecology 0 (0%) 3 (3.4%) 3 (0.9%) 
Other 8 (3.5%) 5 (5.7%) 13 (4.1%) 
 
 86% of patients were first seen by urology. 
 A significantly higher proportion of men than women (90% vs 73%) were first seen by urology P<0.01. 
 22% of women were initially on a non-urology pathway. 
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Symptoms at Presentation 
 
Table 11: Symptoms at presentation 
Symptoms* 2010 & 2011 
 Male (n=264) Female (n=98) Total (n=362) 
Macroscopic haematuria (visible blood in urine) 216 (81.8%) 75 (76.5%) 291 (80.4%) 
Urinary frequency 83 (31.4%) 25 (25.5%) 108 (29.8%) 
Dysuria (pain on passing urine) 50 (18.9%) 18 (18.4%) 68 (18.8%) 
Urinary urgency 38 (14.4%) 13 (13.3%) 51 (14.1%) 
Lower abdominal/back pain 46 (17.4%) 33 (33.7%) 79 (21.8%) 
Weight-loss 31 (11.7%) 18 (18.4%) 49 (13.5%) 
Lethargy 7 (2.7%) 18 (18.4%) 25 (6.9%) 
*Patients may have multiple symptoms and be counted more than once 
 
 Macroscopic haematuria (visible blood in urine) was the most common presenting symptom (80%). 
 Women were more likely than men to present with abdominal pain (P<0.01), lethargy (P<0.01), and weight 
loss (P=0.10), suggesting more advanced stage at presentation. 
 
Symptom Duration 
 
 Duration of macroscopic haematuria was recorded for 77% of patients presenting with haematuria (Table 
12). 
 58% of patients with duration recorded, reported haematuria for more than 4 weeks before presentation, 
12% more than 6 months. 
 Although the proportion of patients reporting haematuria for less than 4 weeks was greater for men 
(44.3%) than women (33.9%), this was not significant (p=0.17). 
 
Table 12: Duration of macroscopic haematuria (obvious blood in the urine) 
Duration Patients with macroscopic haematuria 
(% of those with recorded duration) 
 Male (n=167) Female (n=56) Total (n=223) 
Under 7 days 27 (16.2%) 5 (8.9%) 32 (14.3%) 
1 - 4 weeks 47 (28.1%) 14 (25.0%) 61 (27.4%) 
1 - 3 months 50 (29.9%) 19 (33.9%) 69 (30.9%) 
3 - 6 months 24 (14.4%) 11 (19.6%) 35 (15.7%) 
6 - 12 months 9 (5.4%) 5 (8.9%) 14 (6.3%) 
> 12 months 10 (6.0%) 2 (3.6%) 12 (5.4%) 
 Male (n=216) Female (n=75) Total (n=291) 
Duration not recorded (% of 
patients with haematuria) 49 (22.7%) 19 (25.3%) 68 (23.4%) 
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 There was no significant difference in the distribution of macroscopic haematuria symptom duration 
between men and women (P>0.05) (Fig. 7). 
 When vague symptoms (lethargy, lower abdominal/back pain, weight loss) were grouped together, there 
was no significant difference in symptom duration (not shown) between men and women. 
 
Figure 7: Distribution of recorded macroscopic haematuria duration 
 
 
Diagnosis: Investigations 
 
Table 13: Diagnostic and staging investigations 
Investigation 2010 & 2011* 
 Male Female Total 
Cystoscopy 257/262 (98.1%) 96/98 (98.0%) 353/360 (98.1%) 
TURB** 252/264 (95.5%) 93/98 (94.9%) 345/362 (95.3%) 
CT Scan 192/261 (73.6%) 84/98 (85.7%) 276/359 (76.9%) 
Ultrasound Scan 150/264 (56.8%) 59/97 (60.8%) 209/361 (57.9%) 
MRI Scan 38/263 (14.4%) 16/98 (16.3%) 54/361 (15.0%) 
PET Scan 3/263 (1.1%) 2/98 (2.0%) 5/361 (1.4%) 
Chest X-ray 85/264 (32.2%) 40/98 (40.8%) 125/362 (34.5%) 
Bone Scan 51/263 (19.4%) 26/98 (26.5%) 77/361 (21.3%) 
Urogram 57/263 (21.7%) 13/98 (13.3%) 70/361 (19.4%) 
At least one scan 264/264 (100.0%) 98/98 (100.0%) 362/362 (100.0%) 
* The denominator is the total number of patients adjusted for patients that had a record in their notes stating that they either 1) did not attend, 2) were too 
unfit, or 3) refused 
** Transurethral resection of bladder 
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 98% of patients had a cystoscopy; of these patients 98% (345/353) had a TURB, while 76% (267/353) of 
cystoscopy patients had a CT scan. 
 96% of patients with muscle invasive bladder cancer (TNM stage 2, 3 or 4) had either a CT or an MRI 
scan (not shown). 
 
Basis of Diagnosis 
 
Table 14: Basis of diagnosis 
Method of diagnosis 2010 & 2011 
 Total (n=362) 
Histologically verified 352 (97.2%) 
Clinical investigation alone 10 (2.8%) 
 
 The majority (97.2%) of patients were histologically verified. 
 
Histological Type 
 
Table 15: Histological type 
Histological type 2010 & 2011 
 Male (n=264) Female (n=98) Total (n=362) 
Transitional Cell Carcinoma 233 (88.3%) 78 (79.6%) 311 (85.9%) 
Squamous Cell Carcinoma 8 (3.0%) 7 (7.1%) 15 (4.1%) 
Other* 23 (8.7%) 13 (13.3%) 36 (9.9%) 
*Other includes the following: Neoplasm NOS (12),Carcinoma NOS (6),Carcinoma, anaplastic (1),Pseudosarcomatous carcinoma (3),Small cell carcinoma 
(5), Adenocarcinoma, NOS (2), Muscinous adenocarcinoma (2), Signet ring cell carcinoma (2), Carcinosarcoma, NOS (3) 
 
 Transitional cell carcinoma was the most common histological type (86%). 
 There was a higher proportion (P<0.05) of transitional cell carcinoma among men (88%) than women 
(80%). 
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TNM Stage 
 
The UICC overall integrated stage is shown in Table 16 which is determined on the basis of clinical, imaging 
and pathology data following the first surgical treatment ie. this is the integration of the pathological and clinical 
stage. 
 
Table 16: Integrated TNM Stage (Either recorded in the notes or derived by Registry staff from data in the records) 
Stages 2010 & 2011 
 Male (n=264) Female (n=98) Total (n=362) 
Stage 1: 
Non-muscle invasive (T1 N0 M0) 126 (47.7%) 35 (35.7%) 161 (44.5%) 
Stage 2 & 3: 
Muscle invasive (T2/T3/T4a, NX, N0, M0) 69 (26.1%) 31 (31.6%) 100 (27.6%) 
Stage 4: 
Locally advanced/metastatic (T4b, N0, M0; Any 
T, N1-3, M0; Any T, Any N, M1) 68 (25.8%) 26 (26.5%) 94 (26.0%) 
Stage unknown 1 (0.4%) 6 (6.1%) 7 (1.9%) 
* Patients who were unstaged were either too unfit for investigation/treatment due to comorbidity/patient decision 
 
 It was possible to assign a TNM stage in 98.1% of patients from the clinical notes and electronic patient 
information systems. 
  44.5% of patients were diagnosed with Stage 1 non-muscle invasive disease. 
 A higher proportion of women were unstaged (P<0.01). 
 There was no difference in the overall distribution of disease stage at diagnosis between men and women 
(excluding the unstaged patients) (P<0.23); although men had a higher proportion of Stage 1 non-invasive 
disease than women this was not significantly (P=0.10) different. 
 
TNM Stage by Age  
 
Table 17: Integrated TNM Stage by age group (age groups are defined by tertiles of patient population) 
Stages Age group 
 0-69 (n=128) 70-77 (n=117) 78+ (n=117) All ages (n=362) 
Stage 1 62 (48.4%) 53 (45.3%) 46 (39.3%) 161 (44.5%) 
Stage 2 & 3 22 (17.2%) 37 (31.6%) 41 (35.0%) 100 (27.6%) 
Stage 4 44 (34.4%) 27 (23.1%) 23 (19.7%) 94 (26.0%) 
Stage unknown 0 (0%) 0 (0%) 7 (6.0%) 7 (1.9%) 
* Patients who were unstaged were either too unfit due to comorbidity for further investigation or treatment 
 
 Stage distribution differed (P<0.01) between age groups, with patients aged 70 years or more having a 
higher proportion of Stage 2&3 disease (P<0.01). 
 Younger patients (aged 0-69) had the highest proportion of both Stage 1 and Stage 4 disease. 
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 In the younger age group, although 50% of women (n=13/26) had Stage 4 disease, compared with 30% in 
men (n=31/102), this did not reach significance (P=0.06). 
 All unstaged patients were aged 78 years or older. 
 
Multidisciplinary Team Meetings 
 
Table 18: Multidisciplinary Team meetings (MDM) 
Trust/location of presentation Discussed at MDM: number/total (%) 
Belfast HSCT 93/99 (93.9%) 
Northern HSCT 52/59 (88.1%) 
South-Eastern HSCT 61/70 (87.1%) 
Southern HSCT 63/69 (91.3%) 
Western HSCT 43/45 (95.6%) 
Private sector 11/19 (57.9%) 
Total 324/362 (89.5%) 
*One patient’s ‘Trust of presentation’ was unknown 
 
 Just under 90% of patients were discussed at an MDM. 
 Patients presenting via the private sector were less likely (P<0.01) to have their case discussed at an 
MDM (58%). 
 38 patients (10.5%) were not discussed at an MDM. Eight of these patients (21.0%) were first seen in the 
private sector. The remaining patients were from the Belfast Trust (6), Northern Trust (7), South Eastern 
Trust (9), Southern trust (6) and Western trust (2). Ten patients (26%) presented via A&E and 16% were 
under regular outpatient urology review. 12/38 (32%) of patients who did not have an MDM recorded died 
within 3 months of their diagnosis. 
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Treatment Modality by TNM Stage 
 
Table 19: Treatment modalities by stage (Modality here refers to main treatment for cancer) 
Treatment modalities TNM Stage 
 
Stage 1 Non-
muscle 
invasive 
(n=161) 
Stage 2&3 
Muscle 
invasive 
(n=100)* 
Stage 4 
Locally 
advanced/ 
metastatic 
(n=94) 
Stage 
unknown 
(n=7) 
Total 
(n=362) 
TURB & intravescial 
chemotherapy ± intravesical 
Bacillus Calmette-Guérin (BCG) 
99 (61.5%) 2 (2.0%)
$
 0 (0%) 0 (0%) 101 (27.9%) 
TURB alone 37 (23.0%) 24 (24.0%)
$
 1 (1.1%) 0 (0%) 62 (17.1%) 
Neoadjuvant chemotherapy & 
radical cystectomy 2 (1.2%) 2 (2.0%) 6 (6.4%) 0 (0%) 10 (2.8%) 
**Cystectomy alone 15 (9.3%) 30 (30.0%) 10 (10.6%) 0 (0%) 55 (15.2%) 
**Cystectomy with palliative 
oncological therapy 1 (0.6%) 4 (4.0%) 12 (12.8%) 0 (0%) 17 (4.7%) 
Radical radiotherapy 2 (1.2%) 17 (17.0%) 0 (0%) 1 (14.3%) 20 (5.5%) 
Palliative radiotherapy alone 2 (1.2%) 15 (15.0%) 23 (24.5%) 0 (0%) 40 (11.0%) 
Chemotherapy and 
radiotherapy (curative intent, 
concurrent/sequential) 1 (0.6%) 3* (3.0%) 0 (0%) 0 (0%) 4 (1.1%) 
Palliative chemotherapy alone 
or with radiotherapy 2 (1.2%) 1 (1.0%) 18 (19.1%) 0 (0%) 21 (5.8%) 
***No active treatment 0 (0%) 2 (2.0%)
$
 24 (25.5%) 6 (85.7%) 32 (8.8%) 
*One patient had a salvage cystoprostatectomy following radical chemotherapy and radiotherapy. **Cystectomy category includes cytstoprostatectomy & 
anterior exenteration. Two of the cystectomies reported above were partial. ***17 patients were not fit for curative treatment due to advanced age and 
comorbidity, 7 patients died within a few months of TURB 
 
Stage 1 (Non-muscle invasive disease, n=161, Table 19) 
 The majority of patients with Stage 1 (non-muscle invasive disease), 139/161 (86%) had organ-conserving 
treatment (i.e. TURB, or radical oncology). Just under two thirds (62%) received courses of intravesical 
chemotherapy and/or intravesical Bacillus Calmette-Guérin (BCG) therapy. Just under a quarter (23%) 
had local tumour resection (TURB) alone with repeat cystoscopy/biopsy to ensure disease eradication. 
 11% of Stage 1 patients underwent radical cystectomy. 
 
Stage 2 & 3 (Muscle invasive disease, n=100) 
 A third (36%) of patients with muscle invasive disease (Stage 2&3) had major surgical resection while 20% 
of patients had organ-conserving curative intent oncological therapy. A further 16% had palliative 
oncological treatment. 
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 In total 27% of patients with muscle invasive disease (Stage 2&3) had localised therapy only (TURB).  
After MDM discussion (23/27 patients) and oncology assessment (10 patients) significant co-morbidities 
and/or poor performance status deemed patients unsuitable for active treatment. (Median age 83 years 
with 70% aged 80+ years).  Three of the four patients not discussed at MDM died soon after diagnosis. 
 
Stage 4 (Locally advanced/metastatic, n=94) 
 Just under one third (n=28) of patients with locally advanced/metastatic disease (Stage 4) had radical 
cystectomy with 6 patients having pre-operative chemotherapy and 12 patients requiring adjuvant 
palliative radiotherapy for residual/progressive disease following cystectomy. One quarter (n=23) of 
patients were treated with palliative radiotherapy, while 26% of patients received supportive palliative care 
alone. 
 
Surgical Procedures 
 
Table 20: Surgical procedures performed 
Procedures 2010 & 2011 
 Male (n=264) Female (n=98) Total (n=362) 
TURB 252 (95.5%) 93 (94.9%) 345 (95.3%) 
Cystoprostatectomy 52 (19.7%) — 52 (14.4%) 
Cystectomy 10 (3.8%) 6 (6.1%) 16 (4.4%) 
Anterior exenteration of pelvis 1 (0.4%) 14 (14.3%) 15 (4.1%) 
 
 95% of patients had a TURB. 
 83 surgical resections were performed: cystoprostatectomy (52), cystectomy (16), and anterior 
exenteration of pelvis (15). 
 There was no significant difference in the major resection rate between men and women, even when 
adjusted for age and stage of disease. 
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TURB 
 
Table 21: Trust/Hospital/Location of TURB (One procedure is reported per patient) 
Trust/ Hospital/Location TURB 
Belfast City Hospital 100 (29.0%) 
Mater Infirmorum Hospital 16 (4.6%) 
Belfast HSCT 116 (33.6%) 
Causeway Hospital 48 (13.9%) 
Mid-Ulster Hospital 1 (0.3%) 
Whiteabbey Hospital 1 (0.3%) 
Northern HSCT 50 (14.5%) 
Ulster Hospital 56 (16.2%) 
South-Eastern HSCT 56 (16.2%) 
Craigavon Area Hospital 53 (15.4%) 
Daisy Hill Hospital 15 (4.3%) 
Southern HSCT 68 (19.7%) 
Altnagelvin Hospital 40 (11.6%) 
Western HSCT 40 (11.6%) 
Ulster Independent Clinic 15 (4.3%) 
Private Sector 15 (4.3%) 
Total 345 
 
 A third of all TURB’s were performed in the Belfast Trust. 
 
Major Surgery 
 
Table 22: Trust/Hospital/Location of Major Surgery* 
Trust /Hospital/Location Major surgery* 
Belfast City Hospital 77 (92.8%) 
Belfast HSCT 77 (92.8%) 
Craigavon Area Hospital 4 (4.8%) 
Southern HSCT 4 (4.8%) 
Altnagelvin Hospital 1 (1.2%) 
Western HSCT 1 (1.2%) 
Ulster Independent Clinic 1 (1.2%) 
Private Sector 1 (1.2%) 
Total 83 
*Major surgery is defined as cystoprostatectomy, cystectomy, or anterior exenteration 
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 The majority (93%, 77/83) of radical cystectomies were performed in the Regional Urology Centre at 
Belfast City Hospital with 4 being performed in the Southern Trust, 1 in the Western Trust, and 1 in the 
private sector. 
 
Urinary Diversion 
 
Table 23: Urinary diversions performed 
Urinary diversions Number of patients (% of total patients) 
 Invasive procedures 
 
Anterior 
exenteration of 
pelvis 
Cysto-
prostatectomy 
Cystectomy Total patients 
Ileal conduit 13 (86.7%) 47 (90.4%) 10 (62.5%) 70 (84.3%) 
Orthotopic (neobladder) 0 (0.0%) 3 (5.8%) 1 (6.3%) 4 (4.8%) 
No recorded urinary diversion 2 (13.3%) 2 (3.8%) 5 (31.3%) 9 (10.8%) 
Total patients 15 52 16 83 
 
 89% (74/83) of patients undergoing major resection had a urinary diversion procedure performed. 
 95% (70/74) of the urinary diversions were ileal conduit, the remainder were orthotopic (neobladder). 
 All (100%) orthotopic (neobladder) and 93% of ileal conduit urinary diversion procedures took place in 
Belfast City Hospital. 
 
Table 24: Surgeon case volumes – number of procedures 
Number of procedures Number of surgeons (% of total procedures) 
 Major surgery* (n=83) 
21-35 2 (66.3%) 
11-20 1 (22.9%) 
2-5 4 (9.6%) 
1 1 (1.2%) 
Total surgeons 8 
*Includes anterior exenteration of pelvis, cystoprostatectomy, cystectomy 
 
 89% of major surgical resections were performed by a uro-oncology surgeon with a case-load volume of 
11 or more major procedures during the audit period. 
 11% were performed by urologists who performed 5 or fewer major procedures during the audit period. 
 8 patients who presented via the private sector had their surgery performed by a uro-oncology surgeon 
who performed ≥19 such operations in 2010 & 2011. 
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Lymph Node Resection 
 
Table 25: Lymph node resection 
Invasive procedure Number of patients with lymph node dissection 
 Number (% of total) Total patients 
Anterior exenteration 12 (80.0%) 15 
Cystoprostatectomy 47 (90.4%) 52 
Cystectomy 10 (62.5%) 16 
Total patients undergoing major surgery* 69 (83.1%) 83 
*Major surgery is defined as having received one of the following procedures: cystoprostatectomy, cystectomy, or anterior exenteration 
 
 83% of patients undergoing major surgery had lymph node resection performed.  The median number of 
lymph nodes examined was 15 (range, 1-35) and the median number of positive nodes was 0 (range, 0-
18). 
 
Incidental Prostate Cancer 
 
 Incidental prostate cancer was detected in 17/54 (32%) of men who had a cystoprostatectomy or an 
anterior exenteration. Gleason scores were as follows: 3+3 (8), 3+4 (4), 4+3 (2), 4+4 (2), 4+5 (1). T-stage 
profile was PT2a (5), pT 2b (2) pT2c (9); one patient had pT3a disease. 
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Communication with Primary Care  
 
Table 26: Information in the GP letter 
Information in the GP letter 2010 & 2011 (n=362) 
Diagnosis 348 (96.1%) 
Management plan 347 (95.9%) 
Diagnosis discussed with patient 242 (66.9%) 
Diagnosis discussed with family 125 (34.5%) 
Palliative care 111 (30.7%) 
 
 Over 95% of patients had their diagnosis and management plan recorded in their GP letter. 
 Two thirds of GP letters mentioned that diagnosis was discussed with the patient, and a third of letters that 
diagnosis had been discussed with their family. 
 In 31% of the letters, palliative care was mentioned. 
 
Patient Information 
 
Table 27: Information provided to patient as recorded in the notes 
Information recorded in notes 2010 & 2011 (n=362) 
Diagnosis discussed with patient 304 (84.0%) 
Diagnosis discussed with relatives 211 (58.3%) 
Treatment plan discussed with patient 290 (80.1%) 
Written information given 139 (38.4%) 
Clinical Nurse Specialist services 134 (37%) 
Clinical trial discussed with patient 2 (0.6%) 
Clinical trial recorded in notes 0 (0%) 
 
 Discussion of diagnosis and treatment plan was recorded in the clinical notes/CaPPS in just over 80% of 
patients.  
 Two patients had a clinical trial discussed with them, but neither was enrolled. 
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Clinical Nurse Specialist 
 
Table 28: Record of Clinical Nurse Specialist during diagnosis/treatment 
Seen by a specialist care nurse 2010 & 2011 
 Male (n=264) Female (n=98) Total (n=362) 
Yes 106 (40.2% 28 (28.6%) 134 (37%) 
No/Not recorded 158 (59.8%) 70 (71.4%) 228 (63% 
 
 37% of patients were recorded as having been seen by a Urology Clinical Nurse Specialist.  This figure 
may be an underestimate as this data may not have been consistently available in the clinical notes or 
CaPPS. 
 
Onward Referrals to other Health Professionals 
 
Table 29: Referral for specialist care 
Referral for specialist care* 2010 & 2011 (n=362) 
Physiotherapist 119 (32.9%) 
Occupational therapist 78 (21.5%) 
Social worker 109 (30.1%) 
Psychologist referral 10 (2.8%) 
Palliative care team 92 (25.4%) 
Palliative care consultant 69 (19.1%) 
Marie Curie nurse 9 (2.5%) 
Macmillan nurse 59 (16.3%) 
Information on support groups 4 (1.1%) 
Hospice 43 (11.9%) 
Community nurse 97 (26.8%) 
No onward referral recorded 140 (39.0%) 
*Patients may have multiple referrals and be counted more than once 
 
 Physiotherapist (33%), social worker (30%), community nurse (27%), and palliative care team (25%) were 
among the most frequent forms of specialist care for onward patient referral. 
 A third of patients (33%) had a referral to palliative/hospice care, i.e. at least one of the following: palliative 
care team, palliative care specialist, Marie Curie nurse, Macmillan nurse, or hospice. 
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Bladder Cancer Pathway: Timelines 
 
Timelines monitor the investigation and treatment-delivery timeliness in the patient care pathway which is 
important when early diagnosis improves outcome. N. Ireland has the following waiting time targets for cancer 
patients (The Northern Ireland Cancer Access Standards18).  
1. 95% of patients urgently referred by GPs as a suspected cancer should begin their first definitive 
treatment within a maximum of 62 days. 
2. 98% of patients diagnosed with cancer (decision to treat) should begin their treatment within a 
maximum of 31 days from the date the decision to treat is made between the patient and the 
responsible consultant. 
 
First definitive treatment 
The TURB counts as the first definitive treatment when carried out with the intention of tumour debulking. For 
cancer access targets TURB remains the first definitive treatment even for patients who require further 
treatment such as cystectomy or oncological therapy. 
 
Table 30: Time from referral to TURB, by referral type* (private patients, patients under-review at time of diagnosis, or 
patients who did not receive a TURB, are excluded) 
Days Primary referral type 
 Route to diagnosis 
 Red flag pathway* GP other A&E 
1-14 1 (<1%) 2 (3.8%) 29 (44.6%) 
15-28 15 (12.6%) 2 (3.8%) 10 (15.4%) 
29-42 22 (18.5%) 1 (1.9%) 4 (6.2%) 
43 or more 81 (68.0%) 48 (90.5%) 22 (33.8%) 
Total 119 53 65 
Mean (days) 77 88.3 40.3 
Median (days) 63 76 16 
*Includes GP red flag referrals (n=66) and consultant upgrades (n=53) 
 
 Patients who were referred to A&E (GP/self-referral) had the shortest duration from time of referral to 
TURB (P<0.05). 
 For patients on a red flag pathway the median time to TURB was 63 days. 13% had TURB within 4 weeks 
of referral, 32% within 6 weeks, while over two thirds waited more than 6 weeks. 
 Patients referred by GPs as routine, urgent/semi-urgent had the longest time from referral to TURB 
(P<0.05).  
 There was no difference in this timelines between men and women (not shown) (P=0.91). 
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Referral to First Seen by Urologist 
 
Table 31: Timeline from referral to first seen by urologist by Trust of presentation (private patients [n=19], or 
patients under-review at time of diagnosis [n=43], are excluded) 
Days Trust of presentation 
 
Belfast Northern 
South-
Eastern 
Southern Western Total 
1-14 25 (29.8%) 12 (24.5%) 32 (50.0%) 30 (50.0%) 16 (41.0%) 115 (38.9%) 
15-28 13 (15.5%) 11 (22.4%) 12 (18.8%) 8 (13.3%) 14 (35.9%) 58 (19.6%) 
29-42 9 (10.7%) 13 (26.5%) 8 (12.5%) 8 (13.3%) 5 (12.8%) 43 (14.5%) 
43 or more 37 (44.0%) 13 (26.5%) 12 (18.8%) 14 (23.3%) 4 (10.3%) 80 (27.0%) 
Total 84 49 64 60 39 296 
Mean (days) 43.0 32.2 24.5 31.7 29.5 33.2 
Median (days) 33.5 32 14.5 15 19 23 
 
 Overall 59% of patients were seen by a urologist within 4 weeks of referral while 27% waited over 6 
weeks. 
 The overall duration from referral received to first seen by urologist was longer for patients presenting in 
the Belfast Trust (P<0.05). 
 A lower proportion of patients presenting in the Belfast and Northern Trusts were seen by a urologist within 
4 weeks (P<0.01), 45% and 47% respectively, compared to 69%, 63% and 77% in the South Eastern, 
Southern and Western Trusts respectively. 
 There was no difference between men and women in duration from referral received to first seen by 
urologist (p=0.93). 
 
Table 32: Timeline from referral to TURB by Trust of first presentation (private patients, patients under-review at 
time of diagnosis, or patients who did not receive a TURB, are excluded) 
Days Trust of presentation 
 
Belfast Northern 
South-
Eastern 
Southern Western Total 
1-14 9 (11.3%) 6 (12.5%) 13 (21.0%) 15 (26.3%) 7 (18.9%) 50 (17.6%) 
15-28 7 (8.8%) 4 (8.3%) 7 (11.3%) 10 (17.5%) 2 (5.4%) 30 (10.6%) 
29-42 7 (8.8%) 5 (10.4%) 9 (14.5%) 3 (5.3%) 6 (16.2%) 30 (10.6%) 
43 + 57 (71.3%) 33 (68.8%) 33 (53.2%) 29 (50.9%) 22 (59.5%) 174 (61.3%) 
Total 80 48 62 57 37 284 
Mean 95.9 65.4 53.8 56.9 77.3 71.3 
Median 88.5 63.5 46.5 45 51 60 
 
 Overall 28% of patients had their cancer diagnosed within 4 weeks of referral, while 61% waited 6 weeks 
or more. 
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 A significantly (P<0.01) higher proportion of patients in the Southern Trust (44%) had a TURB within 4 
weeks of referral compared to the other 4 Trusts (24%). 
 The overall duration from referral received to TURB was longer (median 88 days) for patients presenting in 
the Belfast Trust (P<0.01). 
 
TURB to First MDM Discussion by Trust/Location of Presentation 
 
Table 33: Time from TURB to MDM by Trust/location of presentation (excludes patients whose MDM pre-dates 
TURB) 
Days Trust of presentation 
 
Belfast Northern 
South-
Eastern 
Southern Western 
Private 
sector 
Total 
1-14 15 (17.0%) 21 (44.7%) 16 (27.6%) 26 (52.0%) 30 (81.1%) 1 (9.1%) 109 (37.5%) 
15-28 51 (58.0%) 13 (27.7%) 24 (41.4%) 14 (28.0%) 3 (8.1%) 6 (54.5%) 111 (38.1%) 
29-42 16 (18.2%) 4 (8.5%) 8 (13.8%) 3 (6.0%) 0 (0%) 2 (18.2%) 33 (11.3%) 
43 + 6 (6.8%) 9 (19.1%) 10 (17.2%) 7 (14.0%) 4 (10.8%) 2 (18.2%) 38 (13.1%) 
Total 88 47 58 50 37 11 291 
Mean 24.2 26.4 26.5 23 20.6 31.3 24.6 
Median 20.5 15 21 13 10 22 17 
 
 38% of patients had a MDM discussion within 2 weeks of diagnosis, while one quarter were discussed 4 
weeks or more after diagnosis. 
 
  
 PAGE 36 BLADDER 2010 & 2011 
 
RESULTS 
 
Referral to Treatment Modality 
 
Non-muscle invasive bladder cancer (NMIBC) 
For patients with non-muscle invasive Stage T1 bladder cancer TURB is considered first line therapy. 
 
Table 34: Referral to Treatment for Stage 1 NMIBC (private patients, or patients under-review at time of diagnosis are 
excluded) 
Days Non-muscle invasive Stage T1 bladder cancer 
1-14 8 (6.3%) 
15-28 12 (9.5%) 
29-42 11 (8.7%) 
43-62 21 (16.7%) 
>62  74 (58.7%) 
Total 126 
Median 69 
Mean 81.8 
 
 
 For patients with non-muscle invasive bladder cancer median time to treatment (TURB) was 69 days with 
41% of patients having first treatment within 62 days. 
 
Muscle invasive bladder cancer (MIBC) Stage T2 disease or higher 
Radical cystectomy is the standard treatment for localized MIBC. The use of pre-operative cisplatin-containing 
chemotherapy improves overall survival and is recommended in suitable patients with localized disease who 
have good performance status and adequate renal function10.  Recurrence-free and overall survival have been 
shown to be better in patients undergoing surgery within 90 days of diagnosis19. 
 
Time from referral to first line treatment modality is shown in table 35.  
 
Table 35: Referral to start of first line treatment modality for muscle invasive disease (T2 or higher) 
(private patients, or patients under-review at time of diagnosis are excluded) 
Days Treatment modality 
 
Major surgery*/ 
Pre-operative chemotherapy 
Curative-intent oncological therapy 
(radiotherapy or chemoradiotherapy) 
1-14 0 (0%) 0 (0%) 
15-31 1 (2.0%) 0 (0%) 
32-62 4 (8.3%) 1 (5.9%) 
>62  43 (89.6%) 16 (94.1%) 
Total 48 17 
Mean 128 172.3 
Median 118 171 
*For patients undergoing neoadjuvant chemotherapy the start date of chemotherapy was taken, not the start date of surgery 
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 10.3% of patients with muscle invasive disease had their major surgery or commenced pre-operative 
chemotherapy within 62 days of first referral to secondary care. 
 Median time from referral was 118 days for major surgery and 171 days for curative-intent oncology. 
 
Diagnostic TURB to Treatment Modality 
 
Table 36: TURB to first line treatment modality for muscle invasive disease (T2 or higher), private patients 
excluded 
Days Treatment modality 
From TURB 
Major surgery*/ 
Pre-operative chemotherapy 
Curative-intent oncological therapy 
(radiotherapy or chemoradiotherapy) 
1-14 1 (1.8%) 0 (0%) 
15-31 5 (8.8%) 0 (0%) 
32-62 18 (31.6%) 5 (25%) 
63-90  20 (35.0%) 6 (30%) 
>90 13 (22.8%) 9 (45%) 
Total 57 20 
Mean 71 93.8 
Median 65 84 
*For patients undergoing neoadjuvant chemotherapy the start date of chemotherapy was taken, not the start date of surgery 
 
 42% of patients with muscle invasive disease had their major surgery within 62 days of their TURB. 
 Time to major surgery was greater than 90 days in almost one quarter of patients.   
 Median time from TURB to treatment was 65 days for surgery, 84 days for curative-intent oncology. 
 26% of patients with muscle invasive disease had their curative-intent oncological therapy within 62 days 
of their TURB. 
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Survival 
 
International comparisons of bladder cancer survival identify consistently lower survival in women compared to 
men. In the EUROCARE-4 comparison of cancer survival for patients diagnosed 1995 to 1999, N. Ireland had 
amongst the lowest survival in Europe for women with bladder cancer.  
 
This combined with low incidence of bladder cancer in N. Ireland compared to other European countries likely 
reflects as artefact of data collection as at that time Bladder Cancer figures for N. Ireland reported only 
invasive disease and did not count borderline pTa, pTis level bladder tumours as cancers.  Many other 
registries included these non-invasive tumours in their figures inflating cancer incidence and raising survival 
due to the inclusion of tumours with very good survival.  This has since changed and now like most registries 
NICR includes borderline pTa, pTis tumours.  With this anomaly corrected the survival for bladder cancers in 
N. Ireland is recorded as among the highest in Europe in EUROCARE-5.  However we have small numbers of 
bladder cancers in women and year to year variation is large.  The poorer survival of women with bladder 
cancer is internationally recognised.  In a retrospective study of patients who had undergone radical 
cystectomy, it was found that women were more likely to be diagnosed with primary muscle invasive disease 
than men (85% vs 51%)20.  It has been suggested that women are more likely to be older than men when 
diagnosed, with a direct effect on their survival.  In addition, delayed diagnosis is more likely in women after 
haematuria is observed, as the differential diagnosis in women includes diseases that are more prevalent than 
bladder cancer21.   
 
The following graphs and tables present results of estimating and comparing net survival groups (sex, age, 
stage) using a non-modelling approach, which is like a Kaplan-Meier but using weights to correct for 
background mortality. These estimates give the true unadjusted estimates of net survival of these groups. The 
confidence intervals are set at 95%. The observed survival is included in the tables for comparison. 
 
Figure 8: Net survival of all bladder cancer patients in N. Ireland by sex (2010 & 2011 combined) 
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Table 37: Observed and net survival  
Time from diagnosis Survival 2010 & 2011 (n=362) 
 Male (n=264) Female (n=98) Total (n=362) 
 Observed Survival (with 95% confidence intervals) 
6 months 81.4% (76.2%, 85.6%) 70.4% (60.3%, 78.4%) 78.5% (73.9%, 82.3%) 
1 year 71.2% (65.3%, 76.3%) 56.1% (45.7%, 65.3%) 67.1% (62.0%, 71.7%) 
18 months 60.5% (54.4%, 66.1%) 43.9% (33.9%, 53.4%) 56.0% (50.7%, 61.0%) 
2 years 54.2% (47.9%, 60.1%) 43.9% (33.9%, 53.4%) 51.4% (46.0%, 56.5%) 
 Net Survival 
6 months 82.8% (78.0%, 87.5%) 71.7% (62.5%, 80.8%) 79.8% (75.5%, 84.1%) 
1 year 73.4% (67.7%, 79.0%) 58.2% (48.1%, 68.3%) 69.4% (64.4%, 74.3%) 
18 months 63.6% (57.4%, 69.9%) 46.5% (36.1%, 56.9%) 59.0% (53.6%, 64.4%) 
2 years 58.2% (51.5%, 64.8%) 46.5% (36.1%, 56.9%) 55.3% (49.6%, 60.9%) 
 
 At 2-years after diagnosis, men had 58% net survival while women had 47%. Although, the confidence 
intervals of these net survival estimates are over-lapping, a multivariate analysis, which corrects for age at 
diagnosis, demonstrates that there is a significant difference (P<0.05) in the net survival experience of 
men to women (excess hazard risk of 1.5:1, or 50% higher). However, when stage of disease was added 
to the model, this showed a decline to 1.3:1, or 30% higher risk of cancer death in women (P=0.12, which 
is not significant).  A different distribution of stage at diagnosis between the sexes may be responsible for 
the difference in survival between men and women; however, we would need a bigger study to 
demonstrate this.   
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Figure 9: Net survival of bladder cancer patients in N. Ireland by stage (2010 & 2011 combined) 
 
 
Table 38: Observed and net survival by stage group at diagnosis 
Time from diagnosis Survival 2010 & 2011 (n=355*) 
 
Non-invasive muscle 
(n=161) 
Muscle invasive 
(n=100) 
Locally advanced/ 
metastatic 
(n=94) 
 Observed Survival (95% confidence intervals) 
6 months 95.7% (91.1%, 97.9%) 79.0% (69.6%, 85.8%) 52.1% (41.6%, 61.6%) 
1 year 92.6% (87.3%, 95.7%) 67.0% (56.9%, 75.3%) 26.6% (18.2%, 35.8%) 
18 months 86.9% (80.6%, 91.3%) 49.0% (38.9%, 58.3%) 13.7% (7.6%, 21.5%) 
2 years 81.1% (73.9%, 86.5%) 44.3% (34.2%, 53.8%) 9.7% (4.2%, 18.0%) 
 Net Survival 
6 months 97.4% (94.2%, 100.0%) 80.2% (72.1%, 88.3%) 52.7% (42.6%, 62.8%) 
1 year 95.0% (90.9%, 99.2%) 69.0% (59.5%, 78.5%) 27.1% (18.1%, 36.1%) 
18 months 92.0% (86.3%, 97.6%) 51.3% (41.0%, 61.6%) 14.1% (7.1%, 21.1%) 
2 years 87.8% (80.9%, 94.6%) 46.9% (36.2%, 57.5%) 10.1% (3.4%, 16.9%) 
*7 patients were unstaged 
 
 Large differences (P<0.05) in net survival at 2 years were present between the 3 stage groups: non- 
muscle invasive (88%), muscle invasive (47%), and metastatic (10%). 
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Figure 10: Net survival of patients in N. Ireland by age (2010 & 2011 combined) 
 
 
Table 39: Observed and net survival by age group 
Time from diagnosis Survival 2010 & 2011 (n=362) 
 Age 0-69 (n=128) Age 70-77 (n=117) Age 78-97 (n=117) 
 Observed Survival (95% confidence intervals) 
6 months 85.2% (77.7%, 90.3%) 86.3% (78.7%, 91.4%) 63.3% (53.8%, 71.3%) 
1 year 71.9% (63.2%, 78.8%) 76.1% (67.3%, 82.8%) 53.0% (43.6%, 61.6%) 
18 months 63.3% (54.3%, 71%) 64.0% (54.5%, 71.9%) 40.2% (31.3%, 48.9%) 
2 years 58.7% (49.5%, 66.8%) 60.7% (51.0%, 69.0%) 34.4% (25.9%, 43.1%) 
 Net Survival 
6 months 85.5% (79.3%, 91.6%) 87.3% (81.1%, 93.6%) 65.9% (56.9%, 75.0%) 
1 year 72.4% (64.6%, 80.2%) 77.7% (69.9%, 85.6%) 57.3% (47.6%, 67.0%) 
18 months 64.0% (55.6%, 72.4%) 66.5% (57.5%, 75.5%) 46.1% (36.0%, 56.2%) 
2 years 59.6% (50.8%, 68.3%) 64.0% (54.6%, 73.4%) 42.0% (31.5%, 52.5%) 
 
 At 2 years after diagnosis the older age group (age 78 to 97 years) at diagnosis had significantly poorer 
net survival (42%) (P<0.05) than the younger age groups: 60% and 64% for age groups 0 to 69 and 70 to 
77 respectively (note: net survival takes background mortality into account). 
 The net survival decreased with age which means that older patients are more likely to die from their 
bladder cancer than younger patients even when stage is accounted for. 
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Presentation, Diagnosis and Staging 
 98% of bladder cancer patients diagnosed 2010 and 2011 were included in the audit (n=362 patients). 
 Half of patients were over 74 years and 73% were men. 
 72% were current or ex-smokers. 
 Macroscopic haematuria was the most common presenting symptom (80%). 
 58% of patients with symptom duration recorded had haematuria for at least 1 month and 12% over 6 
months. 
 Women were more likely than men to present with abdominal pain, lethargy and weight loss, possibly 
reflecting later stage of disease at presentation. 
 57% of all patients were referred by their GPs (outpatients and A&E). 
 Overall 18% of patients were referred to outpatients by GPs as red flag suspect cancers and a further 
14.6% were upgraded by consultants to a red flag pathway.  GP referrals to A&E accounted for 10.5% 
while 11% were GP routine/urgent/semi-urgent/ referrals to outpatients. 
 31% of patients referred to outpatients by GPs were upgraded to ‘red flag’ by consultants. 
 21% of patients presented via A&E. 
 Over a quarter of patients first presented to the Belfast Trust. 
 52% of patients first presented in outpatient clinics, with a further 16% first seen at a designated 
haematuria clinic. 
 86% of patients were first seen by urology. 
 73% of patients had seen a urologist within 42 days of referral, 39% within 2 weeks. 
 The duration from referral received to first seen by urologist was longer among patients who presented in 
the Belfast Trust. 
 90% of patients were discussed at MDM – Private patients were less likely to be discussed. 
 98% of patients had a cystoscopy; of these patients 98% had a TURB and 77% had a CT scan. 
 96% of patients with muscle invasive bladder cancer had an CT/MRI scan. 
 97% were histologically verified with 86% having transitional cell carcinoma. 
 98% of patients were staged, 45% Stage 1 and 26% Stage 4 at diagnosis. 
 
Treatment 
 95% of patients had a Trans Urethral Resection of Bladder -TURB. 
 A third of all TURBs were carried out in the Belfast Trust. 
 
 Stage 1 (Non-muscle invasive disease, n=161) treatment modality 
- The majority of patients with non-muscle invasive disease, or Stage 1, (86%, 139/161) had organ-
conserving treatment with 11% (18/161) having radical cystectomy. Just under two thirds (62%) 
received courses of intravesical chemotherapy and/or BCG therapy. Just under a quarter had local 
tumour resection (TURB) with repeat cystoscopy to ensure disease eradication. 
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 Stage 2 & 3 (Muscle invasive disease, n=100) treatment modality 
- A third (36%) of patients with muscle invasive disease (Stage 2&3) had major surgical resection 
while 20% of patients had organ-conserving curative intent oncological therapy. A further 16% had 
palliative oncological treatment. 
- In total 28% of patients with muscle invasive disease (Stage 2&3) had localised therapy only 
(TURB+/- intravesical therapy). Sixteen of these 28 patients were deemed unfit due to advanced age 
and/or comorbidity, and a further 7 patients (25%) died within 3 months of diagnosis. 
 
 Stage 4 (Advanced metastatic, n=94) 
- Just under one third (n=28) of patients with locally advanced/metastatic disease (Stage 4) had 
radical cystectomy with 6 patients having pre-operative chemotherapy and 12 patients requiring 
adjuvant palliative radiotherapy for residual/progressive disease following cystectomy. One quarter 
(n=23) of patients were treated with palliative radiotherapy, while 26% of patients received 
supportive palliative care alone. 
 
 83 major surgical resections were performed: cystoprostatectomy (52), cystectomy (16), and anterior 
exenteration of pelvis (15). 
 The majority (93%) of radical cystectomies were performed in the Belfast City Hospital with 4 being 
performed in the Southern Trust, 1 in the Western Trust and 1 in the private sector. 
 89% of major surgical resections were performed by a uro-oncology surgeon with a case-load volume of 
11 or more major procedures during the audit period. 
 11% were performed by urologists who performed 5 or fewer major procedures during the audit period. 
 83% of patients undergoing major surgery had lymph node resection performed.  The median number of 
lymph nodes examined was 15 (range, 1-35) and the median number of positive nodes  
was 0 (range, 0-18). 
 37% of patients were recorded as having been seen by a Urology Clinical Nurse Specialist.  This figure 
may be an underestimate as this data may not have been consistently available in the clinical notes or 
CaPPS. 
 Incidental prostate cancer was detected in 17/54 (32%) of men who had major surgical resection.  
 
Timelines: Referral to diagnosis and treatment 
 
Referral to First Seen by Urologist and TURB 
 59% of patients were seen by a urologist within 4 weeks of referral while 27% waited over 6 weeks. 
 The overall duration from referral received to first seen by urologist was longer for patients presenting in 
the Belfast Trust (P<0.05). 
 A lower proportion of patients presenting in the Belfast and Northern Trusts were seen by a urologist within 
4 weeks (P<0.01), 45% and 47% respectively, compared to 69%, 63% and 77% in the South Eastern, 
Southern and Western Trusts respectively. 
 Overall 28% of patients had their cancer diagnosed by TURB within 4 weeks of referral, while 61% waited 
6 weeks or more. 
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 A significantly (P<0.01) higher proportion of patients in the Southern Trust (44%) had a cancer diagnosis 
within 4 weeks of referral compared to the other 4 Trusts (24%). 
 Patients who were referred to A&E (GP/self-referral) had the shortest duration from time of referral to 
TURB (P<0.05). 
 For patients on a red flag pathway the median time to TURB was 63 days. 13% had TURB within 4 weeks 
of referral, 32% within 6 weeks, while over two thirds waited more than 6 weeks. 
 Patients referred by GPs as routine, urgent/semi-urgent had the longest time from referral to TURB 
(P<0.05).  
 
Referral to Treatment 
 For patients with non-muscle invasive bladder cancer median time from first referral to secondary care to 
treatment (TURB) was 69 days with 41% of patients having first treatment within 62 days. 
 For patients with muscle invasive disease (T2 or higher) median time from first referral to secondary care 
to major surgery was 118 days and median time to curative-intent oncology was 171 days. 
 
Diagnosis to Treatment 
 42% of patients with muscle invasive disease had their major surgery within 62 days of diagnostic TURB. 
 Time to major surgery from TURB was greater than 90 days in one quarter of patients. 
 Median time from diagnostic TURB to treatment was 65 days for major surgery and 84 days for curative-
intent oncology. 
 
Communication with Primary Care and Patient Information 
 Over 95% of patients had their diagnosis and management plan recorded in their GP letter. 
 Two thirds of GP letters mentioned that diagnosis was discussed with the patient, and a third of letters that 
diagnosis had been discussed with their family. 
 In 31% of the letters, palliative care was mentioned. 
 Discussion of diagnosis and treatment plan was recorded in the clinical notes/CaPPS in just over 80% of 
patients.  
 
Survival 
 Risk of death from bladder cancer was higher for women 1.5:1.  However, when stage of disease was 
taken into account, this reduced to 1.3:1, or 30% higher in women. This however was no longer 
statistically significant.   
 The net survival decreased with age which means that older patients are more likely to die from their 
bladder cancer than younger patients, even when stage is taken into account. 
 2 years after diagnosis, men had 57% net survival while women had 47%. 
 Large differences in net survival at 2 years were present between the 3 stage groups: non-muscle invasive 
(88%), muscle invasive (47%), and locally advanced/metastatic disease (10%). 
 Those over 78 years at diagnosis had significantly poorer net survival (42%), than the younger age 
groups: 60% and 64% for age groups 0 to 69 and 70 to 77, respectively. 
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This work assessed the care pathway of bladder cancer patients in N. Ireland and compliance with 
recommended guidelines for investigation and treatment. It found that patients are managed by well-
functioning multidisciplinary teams that record diagnosis and treatment plans and communicate well with 
primary care.  The majority of major bladder cancer surgery in 2010 & 2011 was performed by speciality uro-
oncology surgeons in the Belfast City Hospital reflecting centralisation of surgery in keeping with clinical 
management guidelines. 
 
We explored reasons for bladder cancer survival differences in women compared to men and confirmed a 10% 
lower survival for women with some, but not all, of this due to later stage of disease at diagnosis. This audit did 
not find any differences in the treatment of men and women. 
 
However as with any service, improvements may be made. 
 A considerable proportion (21%) of bladder cancer patients had an emergency admission via A&E and 
34% of younger patients (aged 0-69) presented with Stage 4 disease (50% in women) which is in 
keeping with late presentation. 
 41% of patients waited over 4 weeks to see a urologist and 61% (almost two thirds) waited at least 6 
weeks from referral to diagnosis. 
 Median time from referral to treatment was 118 days for major surgery and 171 days for curative-intent 
oncology. 
 The proportion of patients recorded as having received assistance from a Clinical Nurse Specialist 
was low at 37%. 
 
Recommendations 
1. The public need to be educated about haematuria as an alarm symptom for cancer. 
2. Reasons for late and delayed presentation should be investigated.  
3. Access to urology services should be assessed regionally. 
4. The pathways for bladder cancer investigation and treatment should be explored to speed up this 
process. 
5. Clinical Nurse Specialists should be available for all patients. 
6. Efforts to reduce the prevalence of smoking should continue as tobacco use is a risk factor. 
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Background  
Anatomy of bladder 
The urinary bladder is located in the pelvis and consists of three layers: the epithelium and subepithelial 
connective tissue, the muscle layer (muscularis) and the perivesical fat layer (Figure 11). Bladder cancer can 
present as a papillary (finger-like) lesion, as a flat pre-malignant (in-situ) lesion ‘carcinoma in-situ’ (CIS) or as 
an infiltrating cancer penetrating the muscle layer which can spread to the surrounding lymph nodes and then 
spread (metastasize) to distant sites. 
 
 
Figure 11: Bladder cancer: The extent (T) of the primary bladder 
cancer: Ta (confined to mucosa), T1 (extends to submucosa), T2-
T4a (invades bladder muscle and surrounding fatty tissue) 
 1. epithelium 2. subepithelial connective tissue 3. muscle 4. perivesical fat 
 
Bladder cancer 
The most common cell type is known as transitional cell carcinoma (TCC). Less than 10% of bladder cancers 
are adenocarcinoma or squamous cell carcinoma or other less common cell types. 
 
Approximately 70% of patients with bladder cancer present with a disease that is confined to the bladder 
mucosa-Stage (Ta, CIS) or submucosa T1.  These categories are grouped together as non-muscle invasive 
bladder cancer (NMIBC) while T2-T4 tumours are classified as muscle invasive (MIBC).  NMIBC are more 
common and have a lower risk of progression than MIBC which has poorer survival.   
  
Bladder tumours are generally categorised by stage and grade. The internationally-agreed UICC TNM Staging 
Classification defines the T (Tumour) category, N (regional nodes) category and M (metastases) category to 
give an overall stage of disease (Stage 1-Stage 4). Grade describes the tumour behaviour ie. how aggressive 
the tumour is likely to be.  Grade and stage are prognostic factors which influence choice of treatment and 
determine outcomes. 
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Risk factors 
Tobacco smoking is the most important risk factor for bladder cancer22,23 causing 50-65% of male cases and 
20-30% of female cases. The incidence of bladder cancer is directly related to the duration of smoking and 
number of cigarettes smoked per day.  
 
Bladder cancer was one of the first cancers shown to be industrially associated with occupational exposure to 
chemicals present in dyes, paints and plastics being the second most important risk factor24 accounting for 20-
25% of all cases. These can cause bladder cancer 5-50 (typically, 10-15) years later. The highest risk is 
associated with aromatic amines which were found in dyes, paints and plastics and are currently found in 
diesel exhaust fumes and other industrial by-products. Occupations associated with increased risk include 
work in textile, dyestuffs, chemical or plastics industries; tyre and rubber manufacture; truck and taxi driving; 
painting and printing; metalwork; work in the cable industry; leather work and hairdressing. These chemicals 
have contributed minimally to the current incidence of bladder cancer in western countries because of more 
stringent occupational regulations. 
 
Bladder schistosomiasis (a parasitic disease) is associated with a five-fold increased risk of urinary bladder 
cancer. Infections with schistosomiasis affect about 600 million people in Africa, Asia, South America, and the 
Caribbean, but is not a risk-factor in N. Ireland.  Other causes of bladder cancer include previous treatment for 
cancer- in particular, radiotherapy to the pelvis and some forms of chemotherapy. 
 
Bladder cancer is much more common in men 2.6:1 and this higher incidence is likely related to 
lifestyle/occupational factors. 
 
Common Symptoms 
Haematuria is the most common symptom in bladder cancer. Stage Ta and T1 tumours do not cause bladder 
pain and rarely present with lower urinary tract symptoms (LUTS) while muscle invasive tumours (T2-T4) 
present commonly with haematuria and other symptoms such as urinary frequency, urgency, dysuria (pain 
passing urine) and pelvic pain relating to urinary obstruction. 
 
Screening 
At the moment there is no reliable screening test for bladder cancer. Testing for blood in the urine would not 
be a useful screening test for the general population as small amounts of blood in urine can be caused by 
infections or kidney problems. Also, the low rate of bladder cancer in the population would impair the feasibility 
and cost-effectiveness of screening. 
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Investigation and diagnosis 
Cancer Services: Investing for the Future. Cancer Working Group Sub-group report on urology cancers3 
recommended that “Rapid access haematuria clinics could be provided in a range of acute hospitals, including 
hospitals which are not cancer units, provided they have strong links with a cancer unit and have the 
appropriate expertise available.” The NICE guidance6, recommends that patients with visible haematuria 
should be referred urgently within two weeks to a dedicated haematuria clinic, so that if bladder cancer is 
diagnosed primary treatment can be started within two months. Ideally, sufficient tests to determine whether 
cancer is present can be carried out during a single visit, but in some cases more sophisticated imaging may 
need to be carried out in a radiology department. 
 
Haematuria clinics should offer the following: 
1. Physical examination, which can identify a palpable pelvic mass, i.e. locally advanced tumour.  
2. Urine testing. Urinary cytology has a high sensitivity for detecting high-grade tumours and good 
specificity for all tumours. It can also detect invisible tumours missed by cystoscopy (see below).  
3. Cystoscopy is where a scope (cystoscope) is passed through the urethra to examine the inner lining of 
the bladder. Cystoscopy has good sensitivity for detecting bladder cancer. Flourescence cystoscopy 
under blue/violet light, which causes tumours to fluoresce, improves the detection rate, particularly in 
CIS. 
4. Biopsy by transurethral resection of the bladder (TURB, see below). 
5. Rapid access, if required, for: 
a. Ultrasound imaging. 
b. Intravenous urography (IVU) which is a general X-ray examination to look at the whole of the 
urinary system, in order to see what is causing symptoms.  
 
Transurethral resection of the bladder (TURB) 
Transurethral resection of the bladder (TURB) is a procedure where a resection loop is passed through the 
cystoscope into the bladder in order to remove/biopsy a bladder lesion. The goal of the TURB is to make a 
correct diagnosis, and in NMIBC to remove all visible lesions (including any CIS). Any abnormal areas of 
epithelium should also be sampled as they can be indistinguishable from CIS. When urine cytology is positive, 
but no visible lesions are present, random biopsies should be taken, as well as upper-tract diagnostics 
performed. The prostatic urethra should be sampled when any of the following occurs: abnormal tissue in 
urethra, CIS is suspected in bladder, positive cytology, tumours located at trigone or bladder neck or multiple 
tumours in bladder. 
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When NMIBC (Ta, T1) has been found a second resection is recommended because there is high-risk of 
residual disease (33-53%), or under-staging (4-25%). Treatment of a Ta/T1 high-grade tumour and a T2 
tumour is completely different, hence the importance of staging. The second resection decreases the 
probability of recurrence, especially when the first TURB is incomplete or lacking sufficient muscle or when T1 
or grade 3 disease is diagnosed. The second TURB should take place within 2-6 weeks.  
 
Multidisciplinary team meeting 
Patients with cancer often have complex care needs that cannot be addressed by a single specialty or 
discipline. This has led to the development of multi-disciplinary teams within the Cancer Network to ensure a 
consistent and equitable approach to planning and managing care. Supporting this approach, there is a role 
for a Clinical Nurse Specialist to coordinate care between settings and providing support, advice and 
information for patients and their carers throughout their illness. Rigorous clinical audit is crucial to maintaining 
and improving quality of outcomes. 
 
Treatment 
 
Non-muscle invasive bladder cancer (NMIBC)9 
Patients with bladder cancer that has not invaded the bladder muscle (CIS, Ta, T1) should be stratified into 
one of three risk groups that will facilitate treatment recommendations based on the probabilities of recurrence 
and progression. Bladder tumours can be risk-stratified into: 
1. Low: primary and solitary Ta tumour < 3 cm size, with G1 tumour grade, and no associated CIS. 
2. Intermediate: any tumour not in low or high risk group. 
3. High: Any of the following: T1 tumour, G3 tumour grade, associated CIS, multiple and recurrent and 
large Ta tumour with G1 or G2 grade. 
 
For patients with low-risk Ta tumours one immediate postoperative instillation of intravesical chemotherapy 
(chemotherapy instilled into bladder cavity) is recommended. 
 
For patients with intermediate-risk Ta T1 tumours one immediate postoperative instillation of intravesical 
chemotherapy should be followed by one year full dose BCG* immunotherapy or further installation of 
chemotherapy for a maximum of 1 year. 
 
Patients with high-risk tumours should receive intravesical full dose BCG installations for 1-3 years or 
cystectomy in highest risk tumours or tumours that are BCG refractory. 
 
 
 
 
 
 
 
 
*Bacillus Calmette-Guérin (BCG) 
 PAGE 52 BLADDER 2010 & 2011 
 
APPENDIX A – BLADDER CANCER: OVERVIEW 
 
Treatment: muscle invasive bladder cancer (MIBC)10 
Patients with MIBC should be referred to the specialist team. MRI or CT scan, if MRI is not available should be 
performed to assess the extent of invasive tumours before radical treatment.  MRI provides better resolution to 
assess invasion in the bladder muscle.  
 
 The treatment of choice for MIBC is cystectomy and is indicated for T2-T4a tumours in the absence of 
metastatic disease.  
 Neoadjuvant cisplatin-containing chemotherapy should be considered in suitable patients.  
 A higher surgical case load reduces morbidity and mortality of cystectomy 
 Delay in cystectomy for more than 3 months from diagnosis increases risk of progression and cancer-
specific death. 
 Lymph node dissection should be an integral part of cystectomy 
 
Urinary diversion after radical cystectomy 
Radical cystectomy and urinary diversion are two steps in the one operation. The type of urinary diversion 
procedure depends on patient comorbidities, functional status and patient preference. 
 
Three alternatives are presently used after cystectomy: 
1. Abdominal diversion: urethrocutaneostomy, ileal or colonic conduit and various forms of a continent 
pouch. 
2. Urethral diversion: various forms of gastrointestinal pouches attached to the urethra as a continent 
orthotopic urinary diversion (neobladder). 
3. Rectosigmoid diversion: procedures such as uretero-rectostomy. 
 
Treatment for non-resectable tumours 
For patients with locally-advanced tumours (T4b, invading the pelvic or abdominal wall), primary radical 
cystectomy is not a curative option, but can be used to palliate symptoms such as bleeding, pain, dysuria and 
urinary obstruction. Cystectomy in patients with locally-advanced disease gives rise to post-operative morbidity 
and mortality. Advanced muscle invasive disease can lead to ureteral obstruction requiring permanent 
nephrostomy.  
 
Bladder-preserving treatment 
For patients who are unsuitable for cystectomy, multimodal therapy (TURB, radiotherapy or 
chemoradiotherapy) is the preferred curative therapeutic approach as it is more effective than radiotherapy 
alone. The rationale for TURB followed by radiation is to achieve local tumour control while cisplatin-containing 
chemotherapy aims at eradication of micrometastasis. Cisplatin-based chemotherapy in combination with 
radiotherapy following TURB results in a complete response rate of 60-80%. 
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Metastatic Disease 
About 10-15% of bladder cancer patients have metastatic disease at diagnosis and approximately half relapse 
following cystectomy. Local recurrence accounts for 30% of relapses while distant metastases are more 
common. Cisplatin-containing chemotherapy can achieve median survival of up to 14 months. In patients unfit 
for cisplatin therapy treatment with carboplatin-containing combination chemotherapy is a therapeutic option.
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Charlson score components - comorbidity and age 
Components Score 
Comorbidity component 
Cerebrovascular Disease 1 
Chronic Pulmonary Disease 1 
Congestive Heart Failure 1 
Connective Tissue Disease 1 
Dementia 1 
Diabetes Without Complications 1 
Liver Disease 1 
Myocardial Infarction 1 
Peptic Ulcer 1 
Peripheral Vascular Disease 1 
Cancer 2 
Diabetes With Complications 2 
Hemiplegia Or Paraplegia 2 
Leukaemia 2 
Lymphoma 2 
Renal Disease 2 
Severe Liver Disease 3 
HIV 6 
Metastatic Cancer 6 
  
Age component 
Age  <40 years 0 
 41—50 1 
 51—60 2 
 61—70 3 
 71—80+ 4 
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